Try our mobile app

Published: 2024-01-10 00:00:00 ET
<<<  go to CHRS company page
EX-99.1 2 chrs-20240110xex99d1.htm EX-99.1
Exhibit 99.1

GRAPHIC

© 2024 Coherus BioSciences. 2023 Revenue Growth Quarter over quarter sales growth from Q1 through Q4 6 2023 Net Revenues ($255 - $260 million) achieved upper end of guidance range Q4 revenues >$90M CIMERLI – Quarter-over-quarter revenue growth after Q-Code April 2023 UDENYCA – Quarter-over-quarter net revenue growth Strong ASP to support Q1 2024 OBI launch Three presentations provide long term market share increase opportunity LOQTORZI –Distributors stocked, patients dosed, sales ramp initiated The preliminary 2023 financial information presented here has not been reviewed by our auditor or audited and is subject to significant change. We have not completed our financial close process. The completed, audited Coherus Fourth Quarter and Full Year 2023 Financial Results are planned for release in March 2024 Exhibit 99.1